Board documents
11-12 December 2014

Board Meeting 21

World Health Organization Geneva, Switzerland.

Minutes:

Resoultions:

R13 - Medicines Patent Pool foundation
R12 - Market intervention to accelerate uptake of new vector control tools
R11 - Unitaid office relocation
R10 - Secretariat functional organisation structure
R9 - Grant management process
R8 - Introduction of point-of-care early infant diagnosis in decentralized settings: creating a market for affordable, effective, and equitable HIV testing of exposed infants
R7 - Open polyvalent platforms for a sustainable access to quality and affordable viral load testing in resource-limited settings
R6 - Rapid, point-of-care urine test to monitor adherence to antiretroviral therapy
R5 - Creating access to low cost EOSCAPE-HIV viral load testing in low and middle income countries
R4 - Market entry of a novel HIV viral load monitoring platform for near point-of-care testing
R3 - Unitaid civil society engagement
R2 - CIFF-Unitaid paediatric HIV diagnostics partnership
R1 - Budget
12-13 June 2014

Board Meeting 20

World Health Organization Geneva, Switzerland.

Minutes:

Resoultions:

R4 - Medicines Patent Pool
R3 - Functional review terms of reference
R2 - No-cost extension – global TB department, WHO “Expand-TB Project”
R1 - Unitaid audited financial statements
05 May 2014

Board Meeting 19 Special Session on Proposals

World Health Organization Geneva, Switzerland.

Minutes:

Resoultions:

R1 - Expand new drug markets for tuberculosis (endTB)
R3 - HIV/HCV Drug affordability project (Coalition Internationale Sida)
R4 - Ensuring access to the HCV treatment revolution for HCV/HIV co-infected patients
R5 - Access to treatment for people living with HIV in middle-income countries
R8 - Achieving catalytic expansion of Seasonal Malaria Chemoprevention services in the Sahel
R9 - LYNX p24 Establishing and sustaining a market-based intervention for early-infant diagnosis of HIV at the point of care
06-07 June 2013

Board Meeting 18

World Health Organization Geneva, Switzerland.

Minutes:

Resoultions:

R10 - Initiatives for the Paediatric ARV market
R9 - Proposal Review Committee (PRC) Evolution
R8 - Establishment of a Steering Group Committee
R7 - Election of Chairs of the Policy and Strategy Committee (PSC), and the Finance and Administration Committee (FAC)
R6 - Support to HIV first line treatments
R4 - Unitaid Risk Management Policy
R3 - 2013 Revised Budget
R1 - Election of Chair
04-05 December 2012

Board Meeting 17

World Health Organization Geneva, Switzerland.

Minutes:

Resoultions:

R25 - CHAI paediatric treatment project – Extension request
R16 - Extension proposal World Health Organization (WHO) prequalification of diagnostics
R16 - Annex World Health Organization (WHO) prequalification of diagnostics
R14 - World Health Organization (WHO) prequalification of medicines
R13 - Annex Medicines for Malaria Venture (MMV)
R13 - 2012 Open Call Medicines for Malaria Venture (MMV) Improving severe malaria outcomes
R12 - Annex to PSI ACTWatch
R11 - Annex to TB Alliance
R11 - 2012 Open Call: TB Alliance, Paediatric TB centre of excellence
R9 - Annex to Lawyers Collective resolution
R9 - 2012 Open call: Lawyers Collective oppositions – preventing patent barriers
R8 - 2012 Paediatric ARV call: Innovation in paediatric market access (IPMA)
R7 - DNDi Annex to Resolution 7
R7 - 2012 paediatric antiretroviral call
R6 - Unitaid strategy 2013-2016
R5 - Medicines Patent Pool
R4 - Five year evaluation of Unitaid
R3 - Support to the Civil Society delegations
R2 - Office of the chair of the executive board
R1 - Budget 2013
R12 - 2012 Open Call PSI ACTwatch2
12-13 June 2012

Board Meeting 16

World Health Organization Geneva, Switzerland.

Minutes:

Resoultions:

R6 - Transition progress of the Unitaid paediatric antiretroviral treatment project to Global Fund grants
R5 - Scaling up access to diagnostics for tuberculosis
R4 - Open polyvalent platforms for a sustainable access to viral load testing
R3 - Finance and accountability committee (FAC) terms of reference
R2 - Budget 2012
R1 - Audited Financial Statements 2010-2011
26-27 March 2012

Board Meeting 15 Special Session

World Health Organization Geneva, Switzerland.

Minutes:

Resoultions:

R3 - CD4 and viral-load testing (Médecins Sans Frontières)
R4 - Quality control for rapid diagnostic tests (Foundation for Innovative Diagnostics)
R5 - Accelerating access to innovative point of care HIV dignostics (CHAI and UNICEF)
R6 - Creating a private-sector market for quality-assured rapid diagnostic tests (Population Services International)
R9 - Assured artemisinin supply services (A2S2)
R10 - Call for paediatric antiretroviral letters of intent
12-13 December 2011

Board Meeting 15

Palais des Affaires étrangères Paris, France.

Resoultions:

R1 - Funding Decision Framework
R2 - Office of the Chair of the Executive Board – budget 2012
R3 - Risk Management
R4 - Review of the processes for the update of the Strategy 2013-2015
R5 - Support for products in late stage field evaluation and registration – market entry
R6 - Paediatric HIV AIDS project extension 2012
R7 - Affordable Medicines Facility malaria extension proposal
R8 - Funding request for the Medicines Patent Pool Foundation
R9 - Budget 2012
R10 - Policy Strategy Committee and Finance and Administration terms of reference and related Governance reforms
1 2 3 4 5 6

2023

October

R16-2023-e

Cost Extension for the Project “Rapid, comprehensive targeted gene sequencing solution for drug-resistant TB diagnosis in LMICs”

July

R15-2023-e

Cost Extension for the Project “Unitaid support to WHO prequalification of medicines and in vitro diagnostics, and to the WHO collaborative procedure for registration”

June

R12-2023-e

Additional funding for the Project ‘Late-Stage Development and Regulatory Approval of the Vayu bCPAP and Low-Flow Blender Circuit Devices’

R11-2023-e

Additional ACT-A investment for the Project “Tools for Integrated Management of Childhood Illness – TIMCI”

R10-2023-e

No-cost extension for COVID-19 Output in the project entitled “Rapid, comprehensive targeted gene sequencing solution for drug-resistant TB diagnosis in LMICs”

R9-2023-e

Additional ACT-A investments to accelerate and expand Unitaid’s support for the development and introduction of molecular diagnostics

R8-2023-e

Extension of authorization to procure COVID-19 therapeutics, with reallocation of unspent ACT-A funds to Unitaid’s Medical Oxygen Portfolio

R14-2023-e

Cost Extension for the Project “Broad One Health Endectocide-based Malaria Intervention in Africa” (BOHEMIA)

1 2 3 4 5 6 26

No posts found.